Press Releases

-       ARO-INHBE targets a known pathway that signals the body to store fat in adipose tissue -       In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 19, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024 , the Company’s Board of Directors approved “inducement” grants to 20 new employees under Rule

- Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway PASADENA, Calif. --(BUSINESS WIRE)--Dec. 11, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase

- In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle PASADENA, Calif. --(BUSINESS WIRE)--Dec. 3, 2024-- Arrowhead Pharmaceuticals, Inc.

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 2, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time:

- Conference Call and Webcast Today, November 26, 2024 , at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Nov. 26, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024 .

- Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years - Arrowhead has potential to receive an additional $300 million in near-term clinical trial

- The New Drug Application is based on positive results from the Phase 3 PALISADE study - People living with familial chylomicronemia syndrome have extremely high triglyceride levels and a substantially higher risk of developing acute pancreatitis and associated long-term complications, including

- Plozasiran induced deep and sustained reductions in triglycerides and impacted a wide spectrum of lipoproteins that may be involved with atherosclerotic cardiovascular disease - Similar responses were observed in patients with genetically confirmed and clinically diagnosed FCS - Mean reductions

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 5, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 26, 2024 , at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024 .